Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0552W HIGH $7.33
Volume
6.65 K
Value Traded
4.40 M
Short % Float
10.05%
-3.59%Week
-2.42%1 Month
-12.95%3 Month
+1.68%6 Month
-97.13%5 Year
-96.45%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
41.77 M
EPS (TTM)
-0.80
P/E Ratio
-
Ent. Value
17.38 M
Total Shares
17.04 M
Float Shares
14.99 M
Insiders
12.10%
Institutions
17.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
VERU Catalyst Timeline
Dated clinical, regulatory and corporate events for Veru Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veru Inc.
861Total events
7Upcoming
159Tier-1 (high impact)
2010 to 2045Coverage
Upcoming catalysts 2
Event history 50
▼Program DiscontinuationsabizabulinFiledCorporate
Veru will no longer explore sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease
chronic inflammation related to atherosclerotic cardiovascular diseasesource ↗
▲Patent GrantedEnobosarmFiledIP / Competition
US patent issued for enobosarm with semaglutide
obesitysource ↗
▲Partnership / LicenseEnobosarmFiledCorporate
Clinical supply agreement with Novo Nordisk for semaglutide
obesitysource ↗
▲Enrollment CompleteEnobosarmFiledTrial
PLATEAU Phase 2b trial enrollment completed with 239 patients
obesitysource ↗
▲Enrollment CompleteEnobosarmFiledTrial
Phase 2b PLATEAU clinical trial fully enrolled with 239 patients
obesitysource ↗
▲Patent GrantedEnobosarmFiledIP / Competition
USPTO issued Notice of Allowance for enobosarm+semaglutide methods of use patent
quality weight losssource ↗
▲Full ResultsEnobosarmFiledClinical Data
Phase 2b QUALITY study completed and positive
obesitysource ↗
▲Patent GrantedEnobosarmFiledIP / Competition
USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide
obesitysource ↗
▲Preclinical PoCsabizabulinFiledPreclinical
Sabizabulin demonstrated potent anticancer activity (IC50=18.2nM) in daraxonrasib resistant pancreatic cancer cell lines
daraxonrasib resistant KRAS-driven metastatic pancreatic cancersource ↗
▲Full ResultsEnobosarmFiledClinical Data
Phase 2b QUALITY study completed and positive
obesitysource ↗
▲Enrollment CompleteEnobosarmFiledTrial
Phase 2b PLATEAU trial completed enrollment exceeding 200 patients
obesitysource ↗
▲Enrollment CompleteEnobosarmFiledTrial
Phase 2b PLATEAU trial fully enrolled with 239 patients
obesity in older patients on GLP-1 RAsource ↗
▲Partnership / LicenseEnobosarmFiledCorporate
Clinical supply agreement with Novo Nordisk for Phase 2b PLATEAU trial
obesitysource ↗
◆Enrollment UpdateEnobosarmFiledTrial
Phase 2b PLATEAU clinical trial actively enrolling
obesitysource ↗
▲First Patient DosedEnobosarmFiledTrial
First patient enrolled in Phase 2b PLATEAU trial of enobosarm + semaglutide for high quality weight loss
obesitysource ↗
◆Oral PresentationPresentation
Veru to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
◆Trial InitiationEnobosarmFiledTrial
Phase 2b PLATEAU clinical study expected to begin
obesitysource ↗
▲FDA Feedback ReceivedEnobosarmFiledFDA Meeting
FDA announced total hip BMD as validated surrogate endpoint for osteoporosis drug development
osteoporosissource ↗
▼Equity OfferingCorporate
Completed public offering for net proceeds of approximately $23.4 million
◆Oral PresentationEnobosarmFiledPresentation
Enobosarm presentation at SCWD 18th International Conference
sarcopenia, cachexia, wasting disorderssource ↗
◆Oral PresentationEnobosarmFiledPresentation
The Veru Experience presentation at SCWD 18th International Conference
sarcopenia, cachexia, wasting disorderssource ↗
◆Oral PresentationPresentation
SCWD Regulatory Workshop: Possible Endpoints for Regulatory Approval of Treatments Addressing Muscle Wasting in the Context of Obesity Therapy
muscle wasting in obesity therapysource ↗
▼Equity OfferingCorporate
Public offering completed for net proceeds of approximately $23.4 million
◆Oral PresentationEnobosarmFiledPresentation
Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function
obesitysource ↗
◆Poster PresentationEnobosarmFiledPresentation
Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide
obesitysource ↗
●Oral PresentationEnobosarmFiledPresentation
Scientific presentations at ObesityWeek 2025
obesitysource ↗
●Oral PresentationEnobosarmFiledPresentation
Presentations at ObesityWeek 2025 and SCWD International Conference
obesitysource ↗
▼Equity OfferingCorporate
Pricing of $25 million public offering of common stock and warrants
▲FDA Feedback ReceivedEnobosarmFiledFDA Meeting
Successful FDA meeting providing regulatory clarity for enobosarm; FDA accepts incremental weight loss as primary endpoint and confirms 3mg dose
obesitysource ↗
▲FDA Feedback ReceivedEnobosarmFiledFDA Meeting
Successful FDA meeting providing regulatory clarity for enobosarm in combination with GLP-1 RA
obesitysource ↗
◆Quarterly UpdateCorporate
Fiscal 2025 third quarter financial results and business update conference call
▲Topline ReadoutEnobosarmFiledClinical Data
Positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study
chronic weight loss managementsource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss financial results and clinical progress
▲PK PD DataEnobosarmFiledClinical Data
Selection of novel modified release oral enobosarm formulation following PK study
chronic weight loss managementsource ↗
▲Patent GrantedEnobosarmFiledIP / Competition
Robust patent estate with protection through 2037 and beyond; new patent applications filed with expected expiry 2046
▲Partnership / LicenseEnobosarmFiledCorporate
Collaboration with Laxxon Medical using SPID-Technology for modified release formulation
◆End Of Phase 2 MeetingEnobosarmFiledFDA Meeting
End of Phase 2 meeting requested with FDA
chronic weight management in older patients receiving GLP-1 RAsource ↗
▲Topline ReadoutEnobosarmFiledClinical Data
Positive topline results from Phase 2b QUALITY Maintenance Extension study of enobosarm
obesity (weight maintenance after GLP-1 discontinuation)source ↗
▲Topline ReadoutEnobosarmFiledClinical Data
Positive topline safety results from Phase 2b QUALITY study
chronic weight management in older patients receiving semaglutidesource ↗
●Oral PresentationPresentation
Virtual Investor KOL Connect segment featuring Veru and Dr. Louis J. Aronne
Past FDA Catalysts and PDUFA Decisions
How VERU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | enobosarm | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$36M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
0.8x
rNPV / MCap
Top 49%
Micro Cap(rank 323 of 658)
Percentile Rank
Veru Inc. faces pipeline headwinds (37/100), with $1.4B risk-adjusted pipeline value, led by Veru-944 in Prostate Cancer Metastatic (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Veru-944 Small moleculeCompletedNCT03646162 | Prostate Cancer Metastatic | Phase 2 | COMPLETED | 93 | Oct 15, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every VERU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| enobosarm | weight reduction in older patients with obesity | Phase 2b | 2026-08-03 | positive study that demonstrated that enobosarm plus semaglutide preserved lean mass and physical function, and led to greater fat loss during the 16 week active weight loss periodRead More | Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10thRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BARNETTE K GARYOfficer (Chief Scientific Officer) | Buy | 1,800 2,300 held | $2.69 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VERU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 295.00 K | 133.52 K |
VERU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VERU ranks across every disease it competes in
Competitive Position is a premium feature
See how VERU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVERU News
VERUVeru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Veru Inc. announced positive preclinical data for sabizabulin, demonstrating its ability to overcome resistance to daraxonrasib in pancreatic cancer. The drug exhibited potent anticancer activity and a favorable safety profile, prompting the company to advance it into a planned Phase 2 clinical trial. This strategic decision reflects Veru's commitment to addressing unmet medical needs in cancer treatment.
Read more →VERUVeru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Veru Inc. announced that its CEO, Dr. Mitchell Steiner, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9, 2026. The company is focused on developing innovative treatments for cardiometabolic and inflammatory diseases, with ongoing clinical trials for its drugs enobosarm and sabizabulin. The Phase 2b PLATEAU study has exceeded enrollment expectations, indicating strong interest in their obesity treatment program.
Read more →VERU▲ +18.9%on this news
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru Inc. reported its fiscal 2026 third quarter financial results, highlighting the full enrollment of 239 patients in its Phase 2b PLATEAU clinical trial. The trial aims to evaluate the efficacy of enobosarm in combination with semaglutide for weight loss. The company anticipates reporting interim analysis results in Q1 2027 and has secured a patent allowance for its combination therapy, extending protection until at least 2044.
Read more →VERUVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Veru Inc. has received a Notice of Allowance from the USPTO for a patent related to enobosarm in combination with semaglutide, aimed at improving weight loss outcomes. The patent, which is expected to be issued, covers various treatment regimens and benefits, including the preservation of lean body mass and improved physical function. This development adds to Veru's growing intellectual property portfolio and supports ongoing clinical studies evaluating enobosarm's effectiveness in older patients with obesity.
Read more →VERUVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Veru Inc. announced it will host a conference call on August 10, 2026, to discuss its fiscal 2026 third quarter financial results and provide a business update. The company is advancing its Phase 2b PLATEAU clinical study evaluating enobosarm for weight reduction in older patients with obesity. Positive results from previous studies highlight the potential of enobosarm as a treatment option.
Read more →VERUVeru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Veru Inc. will participate in a fireside chat at Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. CEO Mitchell Steiner will discuss the company's innovative treatments for obesity and other diseases. The ongoing Phase 2b PLATEAU study aims to evaluate enobosarm's effectiveness in older patients with obesity. Results from interim analyses are expected in early 2027.
Read more →VERUVeru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru Inc. has announced the completion of enrollment for its Phase 2b PLATEAU clinical trial, which aims to evaluate the effects of enobosarm in combination with semaglutide for weight loss in older patients with obesity. The trial exceeded its target of 200 participants, with interim results expected in early 2027. This milestone is seen as crucial for developing a new treatment approach for this demographic.
Read more →VERUVeru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Veru Inc. will present at the 2026 Obesity & Weight Loss Drug Development Summit in Boston, focusing on innovative treatments for obesity. Key presentations include strategies for combating sarcopenic obesity in geriatric patients and advancing regulatory frameworks. The company is also conducting a Phase 2b clinical study to evaluate the efficacy of enobosarm combined with GLP-1 RA therapy.
Read more →VERUVeru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru Inc. reported its fiscal 2026 second quarter results, highlighting progress in the Phase 2b PLATEAU clinical trial for enobosarm combined with semaglutide. The trial is actively enrolling participants and is expected to conduct an interim analysis in early 2027. Financial results show a decrease in operating loss and net loss compared to the previous year.
Read more →VERUVeru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Veru Inc. will host a conference call on May 13, 2026, to discuss its fiscal 2026 second quarter financial results and provide a business update. The company is focused on developing innovative treatments for cardiometabolic and inflammatory diseases, including its late-stage drug enobosarm, which is being evaluated in clinical trials for obesity. The Phase 2b PLATEAU study aims to assess the drug's effectiveness in combination with semaglutide for weight loss.
Read more →VERUVeru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru Inc. has initiated the Phase 2b PLATEAU clinical trial, enrolling its first patient to evaluate the combination of enobosarm and semaglutide for weight loss in older patients with obesity. The trial aims to assess the preservation of lean mass and physical function while enhancing fat loss. Interim results are anticipated in early 2027, with final data expected by the end of that year.
Read more →VERUVeru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Veru Inc. announced that CEO Mitchell Steiner will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company is advancing its clinical programs, notably enobosarm, which has shown positive results in clinical trials targeting obesity and related health issues. Veru aims to conduct further studies, including a planned Phase 2b clinical trial to evaluate enobosarm's effectiveness alongside GLP-1 RA therapy. The detailed study design includes assessments of body composition, physical function, and safety, with enrollment expected to commence in early 2026.
Read more →VERUVeru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Veru Inc. reported its fiscal 2026 first quarter results, highlighting the upcoming Phase 2b PLATEAU trial for enobosarm in combination with semaglutide to address weight loss plateaus in older patients with obesity. The company noted positive outcomes from its previous Phase 2b QUALITY trial and received favorable FDA feedback regarding regulatory pathways for enobosarm. The trial is expected to commence this quarter, with interim results anticipated in early 2027.
Read more →VERU▼ -11.5%on this news
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Veru Inc. will host a conference call on February 11, 2026, to discuss its fiscal 2026 first quarter financial results and provide a business update. The company is focused on developing innovative treatments for cardiometabolic and inflammatory diseases, with ongoing clinical trials for its drugs enobosarm and sabizabulin. The Phase 2b PLATEAU clinical study is set to begin in early 2026, aiming to evaluate the efficacy of enobosarm in patients with obesity.
Read more →VERU▼ -8.6%on this news
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Veru Inc. reported its fiscal year 2025 financial results and highlighted progress in its clinical programs, particularly the enobosarm obesity treatment. Following positive results from the Phase 2b QUALITY study, the FDA has provided regulatory guidance, allowing for a focus on incremental weight loss as a primary endpoint. The company plans to initiate the Phase 2 PLATEAU study in Q1 2026 to further evaluate enobosarm's efficacy in older patients.
Read more →VERUVeru to Report Fiscal Year 2025 Financial Results on December 17th
Veru Inc. will host a conference call on December 17, 2025, to discuss its fiscal year 2025 financial results and provide a business update. The company is focused on developing treatments for cardiometabolic and inflammatory diseases, with notable progress in its enobosarm and sabizabulin programs. The Phase 2b PLATEAU clinical study is set to evaluate enobosarm's efficacy in patients with obesity starting in Q1 2026.
Read more →About Veru Inc.
Headquarters2916 N. MIAMI AVENUE, MIAMI, FL, 33127
BIOPHARMAWATCH ELITE PLUS
Trade the next VERU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime